{
    "title": "111_hr6331",
    "content": "The Act titled \"Generating Antibiotic Incentives Now Act of 2010\" includes provisions for extending the exclusivity period for new qualified infectious disease products. The Act \"Generating Antibiotic Incentives Now Act of 2010\" allows for a 5-year extension of exclusivity period for qualified infectious disease products before approval or licensure. This extension does not apply to supplements or subsequent applications for changes that do not modify the product's structure. The Act \"Generating Antibiotic Incentives Now Act of 2010\" allows for a 5-year extension of exclusivity period for qualified infectious disease products before approval or licensure. This extension does not apply to modifications that do not affect safety or effectiveness for drugs, or safety, purity, or potency for biological products. The Secretary will determine if a drug or biological product is qualified within 30 days of a request, and regulations will be promulgated within 12 months of enactment. The Act \"Generating Antibiotic Incentives Now Act of 2010\" allows for a 5-year extension of exclusivity period for qualified infectious disease products approved under section 505 or 351. A qualified infectious disease product is defined as an antibiotic drug or diagnostic test for treating, detecting, preventing, or identifying resistant gram positive pathogens. The Generating Antibiotic Incentives Now Act of 2010 extends exclusivity for qualified infectious disease products, including drugs for VRSA, VRE, multi-drug resistant gram negative bacteria, multi-drug resistant tuberculosis, and other pathogens deemed significant threats to public health due to drug resistance. This applies to drugs approved after the enactment of the Act. SEC. 4. PRIORITY REVIEW.\n\nChapter V of the Federal Food, Drug, and Cosmetic Act is amended to include a new section, 524A, which mandates priority review for qualified infectious disease products. This means that the Secretary must expedite the approval process for these products within 6 months of application submission.\n\nSEC. 5. FAST TRACK PRODUCT. SEC. 5. FAST TRACK PRODUCT. Paragraph (1) of section 506(a) of the Federal Food, Drug, and Cosmetic Act is amended to include drugs intended for serious or life-threatening conditions or qualified infectious disease products. The Secretary must review and revise FDA guidelines for clinical trials on antibiotic drugs within 1 year of this Act and every 4 years thereafter. The review will address animal models, in vitro techniques, surrogate markers, trial types, and delta values. The Secretary must submit annual reports to Congress on the progress of reviewing and revising FDA guidelines for clinical trials on antibiotic drugs. Sponsors of drugs for qualifying pathogens can request written recommendations for nonclinical and clinical investigations before approval under section 505 of the Federal Food, Drug, and Cosmetic Act. The Secretary can provide written recommendations for nonclinical and clinical investigations for drugs for infectious diseases under section 505 of the Federal Food, Drug, and Cosmetic Act or section 351 of the Public Health Service Act. The term \"biological product\" is defined in section 351 of the Public Health Service Act. The term \"drug\" is defined in section 201 of the Federal Food, Drug, and Cosmetic Act. The term \"qualifying pathogen\" is defined in section 505E of the Federal Food, Drug, and Cosmetic Act. The term \"Secretary\" refers to the Secretary of Health and Human Services, acting through the Commissioner of Food and Drugs."
}